What's Happening?
Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. after the company's stock experienced a significant drop. On October 13, 2025, Tvardi's shares fell by over 80% following the release
of disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101, a treatment for idiopathic pulmonary fibrosis. The trial aimed to evaluate the safety, pharmacokinetics, and exploratory outcomes related to lung function. However, the study did not meet its goals, as the preliminary data showed that the patients' baseline characteristics were similar across treatment arms, except for a lower percent predicted Forced Vital Capacity (FVC) in placebo-treated patients compared to those treated with TTI-101.
Why It's Important?
The investigation by Faruqi & Faruqi highlights the potential legal and financial implications for Tvardi Therapeutics and its investors. The significant drop in stock value could lead to substantial financial losses for shareholders, prompting legal scrutiny. This situation underscores the importance of clinical trial outcomes on the financial health of biotech companies and their investors. The outcome of this investigation could set a precedent for how similar cases are handled in the future, potentially affecting investor confidence in the biotech sector.
What's Next?
Investors who have suffered significant losses are encouraged to contact Faruqi & Faruqi to discuss their legal options. The firm is actively seeking to gather more information and assess the viability of claims against Tvardi Therapeutics. The results of this investigation could lead to legal action, which may involve seeking compensation for affected investors. The biotech industry and investors will be closely monitoring the developments of this case, as it may influence future investment decisions and regulatory scrutiny.
